NEW YORK, Oct. 11, 2011 /PRNewswire/ -- Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the Eastern District of New York on behalf of purchasers of Gentiva Health Services, Inc. ("Gentiva" or the "Company") (NASDAQ: GTIV) common stock between July 31, 2008 and July 20, 2010 (the "Class Period").
For more information, click here: http://zlk.9nl.com/gentiva/.
The complaint alleges that defendants failed to disclose that the Company was improperly increasing the number of in-home therapy visits to patients in order to trigger higher Medicare reimbursement rates. The complaint further alleges that positive statements regarding the Company's business condition and prospects were based on the alleged fraud, and thus were materially false and misleading. As a result of these misleading statements Gentiva shares traded at an artificially high price.
On July 13, 2010, Gentiva revealed that the Company was under investigation by the Securities and Exchange Commission. Since this investigation was announced, Gentiva stock has continued to decline, falling from a high of $30.50 per share in April of 2010 to a recent closing price of $5.60 per share on September 26, 2011.To obtain additional information about your rights, contact Joseph Levi, Esq. either via email at email@example.com or by telephone at (877) 363-5972, or visit http://www.zlk.com/gentiva-health-services-gtiv.html. Levi & Korsinsky has expertise in prosecuting investor securities litigation and extensive experience in actions involving financial fraud and represents investors throughout the nation, concentrating its practice in securities and shareholder litigation. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV